124414-07-9

Upstream product

• 121-71-1 3-Hydroxyacetophenone 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 124425-53-2 tert-Butyl-[3-(1,1-dimethoxy-ethyl)-phenoxy]-dimethyl-silane 

Downstream Products

• 121-71-1 3-Hydroxyacetophenone 
• 681275-04-7 1-(3'-t-butyldimethylsilyloxyphenyl)ethanol 
• 268233-77-8 ethyl 3-[3-(tert-butyldimethylsilanyloxy)phenyl]-butyrate 
• 268232-26-4 3-[3-(tert-butyldimethylsilanyloxy)phenyl]but-2-enenitrile 
• 268232-28-6 ethyl 5-[3-(tert-butyldimethylsilanyloxy)phenyl]-hexa-2,4-dienoate 
• 150731-24-1 tert-butyl dimethyl(3-(prop-1-en-2-yl)phenoxy)silane 
• 191729-33-6 C₁₇H₂₇NO₂Si 
• 1426074-89-6 (5-hydroxybenzofuran-3yl) (3-hydroxyphenyl)methanone 
• 1424343-31-6 2-(3-((tert-butyldimethylsilyl)oxy)phenyl)propanal 
• 1365655-93-1 2-(3-((tert-butyldimethylsilyl)oxy)phenyl)propan-2-ol 
• 1257333-84-8 C₁₈H₂₈O₅Si 
• 1257334-06-7 C₁₈H₃₄O₂Si₂ 
• 1170699-62-3 (E)-N-{1-[3-(tert-butyldimethylsilyloxy)phenyl]ethylidene}-4-methoxyaniline 
• 1180020-55-6 C₂₂H₃₂O₃Si 

Relevant academic research and scientific papers

Platinum(II) Complexes with O,S Bidentate Ligands: Biophysical Characterization, Antiproliferative Activity, and Crystallographic Evidence of Protein Binding

We recently characterized a series of novel platinum(II) compounds bearing a conserved O,S binding moiety as a bifunctional ligand and evaluated their solution behavior and antiproliferative properties in vitro against a representative cancer cell line. O

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:wherein B is a nucleobase selected from the groups (a) to (d):and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

Platinum(ii) O,S complexes as potential metallodrugs against Cisplatin resistance

We report on platinum(ii) complexes with different cinnamic acid derivatives as ligands with cytotoxic activity against Cisplatin resistant ovarian cancer cell line subcultures of SKOV3 and A2780. A typical mechanism of action for platinum(ii) complexes a

DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

The invention provides compounds of formula (I), wherein: R1 is OR11, or NR5R5'; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:(I) wherein B is a nucleobase selected from the groups (a) to (d) and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula (I) wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

HETEROCYCLIC DERIVATIVE AND USE THEREOF

The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like. An sGC activation drug containing a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.

POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Vitamin D analogues

The invention concerns novel bi-aromatic compounds having the formula: which are analogs of vitamin D, the process of preparing them, as well as their use in pharmaceutical compositions in human or veterinary medicine, particularly in dermatology, cancer treatment, treatment of auto-immune diseases, and in organ or tissue transplants. Cosmetic compositions and methods of use are also included.

Regioselectivity in the syntheses of enantiopure 2-benzopyrans through intramolecular cyclization of tethered lactaldehydes. Conformations of the products

Using titanium tetraisopropoxide, the enantiopure tethered lactaldehyde (α′S,2S)-2-(3′-hydroxy-α′-methyl-benzyloxy) propanal (6) is cyclized with complete regio- and diastereoselectivity ortho to the phenolic hydroxyl group to give (1S,3S,4R)-3,4-dihydro-1,3,-dimethyl-2-benzopyran-4,5-diol (7). Similar cyclization of the epimeric (α′R,2S)-lactaldehyde (25) yields solely the corresponding (1R,3S,4R)-4,5-diol (34). The 4,5-diacetate (26), but not (35), undergoes conformational inversion of the heterocyclic ring through significant 4,5-peri interactions between the adjacent acetoxy substituents. Spontaneous cyclizations of the corresponding phenoxide ions of the lactaldehydes (6) and (25), generated by fluoride from their silyl ethers, led to the related 4,7-diols with high regioselectivity through ring-closure para to the aromatic oxygen.